Genelux Corporation (GNLX)
NASDAQ: GNLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GNLX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $103.36M
- EPS (TTM)
- -$0.88
- Dividend yield
- None
- 52-week range
- 1.77 – 5.89
- Day range
- 2.12 – 2.37
- Volume / Avg
- 315.92K / 333.31K
- Beta
- —
- Shares outstanding
- 47.63M
52-week range
GNLX stock today
Genelux (GNLX) closed at $2.17 on Nov 20, down 4.82% (-$0.11), versus the S&P 500's 3.70% decline. Shares are 63.2% below their 52-week high of $5.89, set on Nov 28, 2025 and 22.6% above the 52-week low of $1.77, near the bottom of the past year's range. GNLX is down 50.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.3%.
Genelux has posted a net loss over the last twelve months (EPS of -$0.88), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Genelux
Company profileGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Thomas D. Zindrick J.D.
- Headquarters
- Westlake Village, CA
- Employees
- 25
- IPO year
- 2023
- Website
- genelux.com
Financial highlights
Full financialsIn fiscal 2025, Genelux generated $8,000 in revenue, up 0.0% from fiscal 2024. Genelux reported a net loss of $32.1 million, compared with a loss of $29.9 million a year earlier. Operating margin was -415175.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $8.00K | $8.00K | $170.00K | $11.07M |
| Growth | 0.00% | -95.29% | -98.46% | — |
| Net income | $-32.15M | $-29.87M | $-28.30M | $-5.21M |
| EPS (diluted) | $-0.86 | $-0.95 | $-1.16 | $-0.57 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$18.83+767.74%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.23 vs $-0.19
- Surprise
- -21.05%
GNLX news
All GNLX newsGenelux peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs GNLX |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs GNLX |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs GNLX |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs GNLX |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs GNLX |
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs GNLX |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs GNLX |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs GNLX |
Indexes, lists and sector
Genelux stock FAQ
What is Genelux's stock price today?
GNLX last traded at $2.17 as of Nov 20, 4:00 PM EST, down 4.82% on the day. Prices are delayed at least 15 minutes.
Who is Genelux's CEO?
Mr. Thomas D. Zindrick J.D. is the chief executive officer of Genelux Corporation, which has about 25 employees.
What is the GNLX 52-week high?
The 52-week high for GNLX is $5.89 and the 52-week low is $1.77. The stock is currently 63.2% below its high.